Company
Nuformix PLC
LON:NFX
Nuformix PLC is a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing. The company aims to use its expertise in discovering, developing and patenting novel drug forms, with improved physical properties, to develop new products in new indications that are, importantly, differentiated from the original (by way of dosage, delivery route or presentation), thus creating new and attractive commercial opportunities. Nuformix has a pipeline of preclinical assets with potential for significant value and early licensing opportunities.
51 stories · page 1 of 3
Nuformix showcases proprietary tranilast programme to potential licensing partners
Pre-clinical update underlines progress for company’s NXP002 programme
Nuformix makes headway with lead asset as it continues to build 'robust data package'
Pre-clinical drug NXP002 is being developed to treat idiopathic pulmonary fibrosis
Nuformix appoints former CEO Dan Gooding as exec director, Julian Gilbert as non-exec chairman
Gooding is a co-founder of Nuformix and was its CEO until June 2020
Nuformix gets two presentations approved for leading international respiratory congress
The event is attended by all the major respiratory-focused pharmaceutical companies
Nuformix hoping to develop a 'bio-better' version of AstraZeneca blockbuster
The company is working on an enhanced formulation of AstraZeneca's cancer drug Lynparza
Nuformix initiates inhalation studies using new delivery method
Results are expected to be generated throughout the second half of 2022 as development milestones are achieved
Nuformix chairman resigns to take up new role
Dr Alastair Riddell is departing with immediate effect
Nuformix updates on NXP002, drug pipeline and CEO search
The company provided a comprehensive overview of its prospects